Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Seikagaku’s Herniated Disk Drug Accepted for US FDA Review
May 15, 2024
- Sumitomo Pharma to Kick Off PI Study for Universal Flu Vaccine in Europe
May 15, 2024
- Sumitomo Seeks Label Expansion for Gemtesa in US
May 15, 2024
- Takeda, AC Immune Sign US$2 Billion Alzheimer’s Deal
May 14, 2024
- Sumitomo Pharma Replaces CEO amid Dismal Earnings
May 14, 2024
- Shionogi’s COVID-19 Pill Fails to Show Significant Difference in Global PIII
May 14, 2024
- Blackstone to Take I’rom Group Private in Bid to Address Japan’s Drug Lag
May 14, 2024
- Suzuken Eyes One-Stop Platform for Japan Launch of “Loss” Products
May 14, 2024
- Fycompa Approved for Label Expansion in China: Eisai
May 14, 2024
- Shionogi Renews Record Earnings in FY2023, Driven by Xocova and Xofluza
May 14, 2024
- Lilly’s Gemzar to Exit Japan Market Next Spring under G1 Withdrawal Rule
May 13, 2024
- Sumitomo Splits Non-Pharma “Frontier” Business
May 13, 2024
- Shionogi Nabs Global Rights to Maze’s Pompe Disease Therapy
May 13, 2024
- Amgen Files Otezla for Palmoplantar Pustulosis in Japan
May 13, 2024
- Moderna Set to Develop Cancer Vaccines, Rare Disease Therapies in Japan: New Local Chief
May 10, 2024
- Jardiance Positive in Japanese CKD Patients Too: Subgroup Analysis
May 10, 2024
- Takeda’s Operating Profit Dips by More than Half in FY2023
May 10, 2024
- Japan Ethical Drug Sales Down 2.4% in March: Crecon
May 10, 2024
- Keytruda Best-Selling Drug in Japan for 7th Month in April: Encise
May 10, 2024
- Ono CEO Calls for Full Abolition of Spillover Re-Pricing Rule
May 10, 2024
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…